Bevacizumab Treatment for Diabetic Macular Edema in Brazil
Author Information
Author(s): Ibrahim Larissa Fouad, Soares Aleida Nazareth, Costa Lucas Assis, Domingues Thabata Machado Correia, de Souza Alessandra Hubner
Primary Institution: Faculdade Ciências Médicas de Minas Gerais
Hypothesis
This study aimed to evaluate DME treatment with antiangiogenic drugs, in terms of both visual and economic outcomes within the Brazilian public health system.
Conclusion
The study showed positive clinical results from bevacizumab treatment of DME, with 63.8% of participants improving their visual acuity after one year.
Supporting Evidence
- 62% of patients received three injections over 12 months.
- 63.84% of participants showed improvements in their best corrected visual acuity after 12 months.
- Median reduction in central macular thickness was 39.5 µm after 12 months.
- The total treatment cost for 130 eyes was R$92,577.02.
Takeaway
Doctors used a medicine called bevacizumab to help people with eye problems from diabetes, and many of them saw their vision get better after a year.
Methodology
This was a single-center retrospective study collecting data from medical records of adults diagnosed with DME treated with intravitreal bevacizumab.
Limitations
The study had a limited follow-up period and fewer injections compared to other studies may have affected visual outcomes.
Participant Demographics
The mean age of participants was 63.3 years, with 53% men and 47% women.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website